drugset / Trial / NCT01497496
Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Phase 2
Completed
29 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Celgene Corporation · collabNovartis · collab
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to see if the combination of ofatumumab with high dose methylprednisolone followed by additional treatment with ofatumumab and lenalidomide can help people with relapsed or refractory CLL/SLL get rid of their CLL/SLL for a long period of time. Researchers also want to find out if the combination of ofatumumab with methylprednisolone followed by additional treatment with ofatumumab and lenalidomide is safe and tolerable.
Timeline
- Start
- 2012-01-26
- Primary completion
- 2019-09-25
- Completion
- 2020-03-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | High Dose Methylprednisolone | Unknown | 1000 mg/m2 | — |
| Subject | Lenalidomide | Other / unclassified | 5 mg | — |
| Subject | Lenalidomide | Other / unclassified | 10 mg | — |
| Subject | Ofatumumab | Monoclonal antibody | 2000 mg | — |